Hepatic uptake of epirubicin by isolated rat hepatocytes and its biliary excretion after intravenous infusion in rats

[1]  Chun-Woong Park,et al.  Validation of high-performance liqid chromatography method to determine epirubicin and its pharmacokinetics after intravenous bolus administration in rats , 2013, Journal of Pharmaceutical Investigation.

[2]  K. Arimori,et al.  Inhibition of carrier‐mediated uptake of epirubicin reduces cytotoxicity in primary culture of rat hepatocytes , 2008, Journal of applied toxicology : JAT.

[3]  K. Arimori,et al.  Effect of acute hepatic failure on epirubicin pharmacokinetics after intrahepatic arterial injection in rats. , 2008, Biological & pharmaceutical bulletin.

[4]  Xuyang Peng,et al.  The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. , 2005, Molecular interventions.

[5]  Sukgil Song,et al.  HPLC analysis and pharmacokinetic characteristics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, in rats and beagle dogs. , 2005, Biological & pharmaceutical bulletin.

[6]  J. Hanfelt,et al.  Epirubicin cardiotoxicity: A study comparing low- with high-dose-intensity weekly schedules , 1996, Supportive Care in Cancer.

[7]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[8]  Y. Sugiyama,et al.  Recent Advances in Carrier-mediated Hepatic Uptake and Biliary Excretion of Xenobiotics , 1996, Pharmaceutical Research.

[9]  Y. Lo,et al.  Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Federico Innocenti,et al.  Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. , 2002, British journal of clinical pharmacology.

[11]  Y. Lo,et al.  Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. , 2000, Biochemical pharmacology.

[12]  J. Zalcberg,et al.  Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line , 1999, British Journal of Cancer.

[13]  K. Chihara,et al.  Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells , 1996, Cancer Chemotherapy and Pharmacology.

[14]  Y. Sugiyama,et al.  Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. , 1993, The American journal of physiology.

[15]  J. Robert.  Epirubicin. Clinical pharmacology and dose-effect relationship. , 1993, Drugs.

[16]  T. Iga,et al.  Uptake of organic anions by isolated rat hepatocytes. A classification in terms of ATP-dependency. , 1992, Journal of hepatology.

[17]  H. Fujita,et al.  Pharmacokinetics of doxorubicin, (2"R)-4'-O-tetrahydropyranyl-adriamycin and aclarubicin. , 1986, The Japanese journal of antibiotics.

[18]  T. Oki,et al.  [Studies on the absorption, excretion and distribution of aclacinomycin A: absorption, excretion and distribution of 14C- or 3H-aclacinomycin A in mice, rats and rabbits (author's transl)]. , 1980, The Japanese journal of antibiotics.

[19]  D. Eaton,et al.  Uptake of unconjugated bilirubin by isolated rat hepatocytes. , 1979, The American journal of physiology.